In a report released today, Matthew O’Brien from Piper Sandler assigned a Buy rating to Glaukos (GKOS – Research Report), with a price target of $105.00. The company’s shares closed yesterday at $96.11.
O’Brien covers the Healthcare sector, focusing on stocks such as Medtronic, Sight Sciences, and Atricure. According to TipRanks, O’Brien has an average return of 7.2% and a 53.18% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Glaukos with a $91.56 average price target, implying a -4.73% downside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $105.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $97.24 and a one-year low of $44.26. Currently, Glaukos has an average volume of 827.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Glaukos (GKOS) Company Description:
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
Read More on GKOS:
- Glaukos backs FY24 revenue view $350M-$360M, consensus $352.71M
- Glaukos raises FY23 revenue view to $313M from $307M-$310M, consensus $309.02M
- Glaukos reports preliminary Q4 revenue $81M, consensus $76.66M
- MIGS LCD withdrawals ‘takes some upside off table’ for Glaukos, says Truist
- Palmetto GBA announcement creates uncertainty for Glaukos, says BTIG
